BPC 157 Vascular Study: Nitric Oxide Research

For years, most of the vascular research on BPC 157 has been conducted in animal models, leaving clinicians and patients with limited human tissue data to reference. A study published in the Journal of Clinical Medicine in May 2026 has begun to change that picture. Researchers tested BPC 157 directly on human internal mammary artery segments and found evidence suggesting the peptide may promote blood vessel relaxation through an endothelium-dependent nitric oxide (NO) mechanism — a finding that adds an important early layer of human-relevant mechanistic evidence to the existing literature.

What This Study Found

The research team, led by Yildirim, Dastan, Demeli Ertus, and colleagues, used residual internal mammary artery (IMA) segments collected from 12 patients undergoing elective coronary artery bypass graft (CABG) surgery. These segments — tissue that would otherwise be discarded — were divided into two categories: rings with an intact endothelial lining and rings from which the endothelium had been deliberately removed.

Each preparation was first contracted using phenylephrine, a standard pharmacological tool for inducing arterial tension in laboratory settings. Researchers then applied cumulative doses of BPC 157 (ranging from 0.01 to 1 mg/mL) and measured the resulting changes in vascular tone.

The study found that BPC 157 produced a concentration-dependent reduction in contraction in both groups — meaning that as the dose increased, the degree of relaxation also increased. However, the relaxation response was significantly greater in rings where the endothelium was left intact compared to those where it had been removed (p < 0.05).

To investigate whether nitric oxide signaling was responsible for this difference, the researchers pre-treated a subset of intact rings with L-NAME (Nω-nitro-L-arginine methyl ester), a well-established inhibitor of nitric oxide synthase (NOS) — the enzyme responsible for producing nitric oxide in vascular tissue. The results were telling: L-NAME increased contractile responsiveness and substantially reduced the vasorelaxant effect of BPC 157. Under NOS inhibition, the difference between endothelium-intact and endothelium-denuded rings progressively narrowed, and their concentration-response curves eventually converged at higher BPC 157 concentrations.

Analysis of maximum response (Emax) values confirmed that endothelial integrity markedly enhanced the maximal vasorelaxation produced by BPC 157, and that this advantage was largely abolished when nitric oxide production was blocked. Importantly, the persistence of some relaxation even after NOS inhibition suggests that BPC 157 may also act through additional, endothelium-independent mechanisms — though the study does not identify these with certainty.

Clinical Significance

Nitric oxide is one of the most important regulators of vascular health. Produced by endothelial cells lining the interior of blood vessels, NO signals surrounding smooth muscle to relax, reducing arterial resistance and improving blood flow. Endothelial dysfunction — characterized by impaired NO production — is considered an early and central feature of cardiovascular disease, contributing to conditions such as hypertension, atherosclerosis, and coronary artery disease.

The fact that BPC 157 appears to engage this pathway in human arterial tissue, rather than only in animal models, represents a meaningful step forward. Prior preclinical research had suggested BPC 157 possesses cytoprotective, pro-angiogenic, and NO-modulating properties, but translating those findings to human physiology requires human tissue evidence — which is precisely what this study begins to provide.

The use of internal mammary artery segments from CABG patients is also methodologically notable. The IMA is considered a gold-standard conduit in cardiac surgery precisely because of its functional endothelium and long-term patency. Demonstrating vasorelaxant effects in this specific vessel type may carry particular relevance for understanding how BPC 157 could theoretically interact with coronary circulation — though the authors are careful to note that further molecular and in vivo studies are required to clarify clinical relevance.

The study does not evaluate BPC 157 as a treatment for any cardiovascular condition, and no clinical outcomes data were collected. Researchers suggest this work should be viewed as early mechanistic evidence that warrants further investigation, not as a basis for clinical recommendations.

Current Access and Compliance Context

BPC 157 is a synthetic pentadecapeptide — a chain of 15 amino acids derived from a protein found in gastric juice. It is not currently approved by the U.S. Food and Drug Administration (FDA) or equivalent regulatory agencies in most countries for the treatment or prevention of any medical condition. In the United States, BPC 157 is not available as a licensed pharmaceutical and has been subject to regulatory scrutiny regarding its use in compounded preparations.

Individuals who access BPC 157 do so through research channels or, in some jurisdictions, through compounding pharmacies operating under the oversight of licensed medical providers. The regulatory landscape continues to evolve, and anyone considering BPC 157 for any purpose should do so only under the supervision of a qualified, licensed healthcare professional familiar with peptide pharmacology and current compliance standards.

The Peptide Association maintains a directory of healthcare providers who are knowledgeable about peptide research and can guide patients through evidence-based, compliant options.

What Patients Should Know

If you have encountered information about BPC 157 and are curious about its potential role in vascular health, here are several key points to keep in mind based on the current state of evidence:

This is early-stage mechanistic research. The Yildirim et al. study is a laboratory investigation using isolated arterial tissue. It does not tell us how BPC 157 behaves in a living human body, what doses might be relevant, or whether any clinical benefit would result from its use in patients with cardiovascular conditions.

The endothelium matters. The study suggests that a healthy, intact endothelium significantly enhances BPC 157's vasorelaxant effects. This raises questions about how the compound might behave in individuals with pre-existing endothelial dysfunction — a population that includes many people with cardiovascular risk factors. These questions remain unanswered by current research.

Residual effects suggest complexity. Even when nitric oxide production was blocked, BPC 157 still produced some degree of relaxation. Researchers suggest this points to additional mechanisms beyond the NO pathway, though those mechanisms have not yet been characterized in this context.

Medical supervision is essential. Given the absence of approved indications and the evolving regulatory environment, no patient should use BPC 157 outside of a supervised medical context. A knowledgeable provider can help assess whether participation in research or access through legal channels is appropriate for your individual situation.

Conclusion

The 2026 study by Yildirim, Dastan, Demeli Ertus, and colleagues represents a meaningful contribution to the scientific understanding of BPC 157's vascular properties. By demonstrating concentration-dependent vasorelaxation in human arterial tissue — and linking that effect primarily to endothelium-dependent nitric oxide signaling — the researchers have provided some of the first human-relevant mechanistic data for this peptide's cardiovascular activity. The study suggests this is a promising avenue for continued investigation, while appropriately calling for further molecular and in vivo research before any clinical conclusions can be drawn.

As the science continues to develop, staying informed through credible, evidence-based sources is the best way to evaluate emerging research. If you are interested in speaking with a healthcare provider who is knowledgeable about peptide research, visit peptideassociation.org/find-a-doctor to find a qualified professional in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The research summarized here represents early-stage laboratory findings. BPC 157 is not approved by the FDA or equivalent regulatory bodies for the treatment or prevention of any medical condition. Always consult a qualified, licensed healthcare professional before making any decisions related to your health or medical care.

---

Citation: Yildirim AK, Dastan AO, Demeli Ertus M, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine. 2026;15(9):3488. doi:10.3390/jcm15093488. PMID: 42123221.